Mantle Cell Lymphoma (MCL)
from OrphaChat — a Rare Disease Podcast Hosted by RCH
These sources collectively examine the diagnostic landscape, therapeutic advancements, and safety profiles associated with B-cell malignancies, particularly mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia. They detail the role of the cyclin D1 biomarker in diagnosing MCL and discuss various treatment modalities, including covalent and non-covalent BTK inhibitors, bispecific antibodies like glofitamab, and CAR T-cell therapies. A significant portion of the text is dedicated to managing treatment-related toxicities, specifically cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Furthermore, the documents provide updated clinical guidelines from the NCCN and real-world data on drug efficacy and patient survival. Specific attention is given to relapsed or refractory cases, highlighting ongoing clinical trials and the emerging importance of measurable residual disease (MRD) monitoring. Overall, the collection serves as a comprehensive overview of modern oncological strategies and the complications arising from potent immunotherapies.
Embed this episode
No transcript yet.